KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Other financing activities (2016 - 2025)

Biogen (BIIB) has 17 years of Other financing activities data on record, last reported at -$1.3 million in Q4 2025.

  • For Q4 2025, Other financing activities fell 119.7% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached $5.0 million, changed N/A, while the annual FY2025 figure was $5.0 million, N/A changed from the prior year.
  • Other financing activities reached -$1.3 million in Q4 2025 per BIIB's latest filing, down from $6.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at $11.4 million in Q1 2021 and bottomed at -$71.5 million in Q4 2021.
  • Average Other financing activities over 5 years is -$4.1 million, with a median of $1.0 million recorded in 2022.
  • The widest YoY moves for Other financing activities: up 3550.0% in 2024, down 604.0% in 2024.
  • A 5-year view of Other financing activities shows it stood at -$71.5 million in 2021, then skyrocketed by 75.1% to -$17.8 million in 2022, then skyrocketed by 145.51% to $8.1 million in 2023, then dropped by 18.52% to $6.6 million in 2024, then tumbled by 119.7% to -$1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were -$1.3 million in Q4 2025, $6.2 million in Q3 2025, and -$1.2 million in Q2 2025.